BridgeBio Pharma
BBIO
211 hedge funds and large institutions have $6.56B invested in BridgeBio Pharma in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 18 closing their positions.
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
34% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 62
5% more funds holding
Funds holding: 201 → 211 (+10)
0% more funds holding in top 10
Funds holding in top 10: 15 → 15 (0)
2.1% less ownership
Funds ownership: 95.6% → 93.5% (-2.1%)
25% less capital invested
Capital invested by funds: $8.7B → $6.56B (-$2.14B)
51% less call options, than puts
Call options by funds: $19.6M | Put options by funds: $40.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$34.4M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$30.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$23.1M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$17.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$102M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$59.9M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$43.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$41M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.7M |
BBIO Hedge Fund Activity: Q3 2021 in Review
211 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2021, worth a combined $6.56B — down 25% from $8.7B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new BBIO positions and 18 closed out — a net gain of 12 holders — while 83 added to existing stakes and 62 trimmed.
The largest buyer was BlackRock, adding an estimated $34.4M. The largest seller was Vanguard Group, cutting an estimated $102M.
- 211 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2021, up from 201 in Q2 2021.
- Funds reported $6.56B of BridgeBio Pharma stock for Q3 2021, down 25% quarter-over-quarter.
- 30 funds opened new BridgeBio Pharma positions in Q3 2021 and 18 closed out, a net change of +12 holders.
- The largest BridgeBio Pharma buyer in Q3 2021 was BlackRock, an estimated $34.4M added.
- The largest BridgeBio Pharma seller in Q3 2021 was Vanguard Group, an estimated $102M sold.
Based on aggregated 13F filings for Q3 2021.